Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
BioLineRx Ltd. A biopharmaceutical firm developing and commercializing therapies for oncology and rare diseases.	United States of America	BLRX
BIOMARIN PHARMACEUTICAL INC Develops and commercializes therapies for rare, life-threatening genetic diseases.	United States of America	BMRN
BioMaxima S.A. Manufacturer of IVD solutions including tests, reagents, and equipment for medical labs.	Poland	BMX
Biomea Fusion, Inc. Develops oral small molecules for metabolic diseases like diabetes and for specific cancers.	United States of America	BMEA
BIOMERICA INC Develops diagnostic tests for GI, inflammatory diseases, and diabetes for lab and at-home use.	United States of America	BMRA
bioMérieux Provides in vitro diagnostic solutions for clinical and industrial microbiology.	France	BIM
BiomX Inc. Develops phage therapies to target harmful bacteria in chronic diseases like cystic fibrosis.	United States of America	PHGE
BioNTech SE Pioneering mRNA immunotherapies and vaccines to combat cancer and infectious diseases.	United States of America	BNTX
BioPorto IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.	Denmark	BIOPOR
BioRestorative Therapies, Inc. A clinical-stage company developing stem cell therapies for pain, metabolic disorders, and aesthetics.	United States of America	BRTX